glp-1 obesity drug news october 9 2025 A wave of new #GLP1 options for type 2 #Diabetes and #Obesity was a major focus at #ADA2026. In the latest JAMA Medical podcast, Jennifer Abbasi interviews Rita Kalyani, MD Outlook for obesity in 2025:

10.1016/j.mam.2012.05.005 Mol

"Clinical evaluation of GraftCyte moist dressings on hair graft viability and quality of healing"

doi: 10.1016/j.biopha.2017.04.078

Because our pets face categories of toxins that behave differently: lipophilic pesticides, water-soluble drug residues, inhaled VOCs, endocrine-disrupting plastics, oxidative food byproducts, and neuro-excitatory parasiticides, only a multimodal approach can match the diversity of the burden

GIM: GABARAP interacting motif

Each of these medications has gone through rigorous clinical trials demonstrating safety and efficacy, which is a level of evidence that currently doesnt exist for over-the-counter GLP-1 patch products